Thus the anti-tumor immune response is inhibited by making tumor cells unrecognizable to immune cells.[2] PD-1/PD-L1 targeted inhibitors include monoclonal antibodies, polypeptide inhibitors, small molecule inhibitors, and anti-cancer vaccines. This evidence concerns the gene CD274 and cancer.